Printer Friendly

MedicalCV, Inc. Revises Timing Expectations for Commercial Launch of Minimally Invasive System.

MINNEAPOLIS -- MedicalCV, Inc. (OTCBB:MCVI), www.medcvinc.com, announced today that it has received correspondence from the U.S. Food and Drug Administration commenting on the company's 510(k) application for its minimally invasive surgical ablation system. The company expects to respond to such comments within the next 30 days. As a consequence of the continued review of the company's application, the company no longer expects to receive 510(k) clearance on a timeline that would permit commercial launch of its minimally invasive system this calendar year.

About MedicalCV, Inc.

MedicalCV, Inc., a cardiovascular surgery device manufacturer, focuses on the development and introduction of products designed to improve patient outcomes through the early treatment of cardiovascular disorders and disease, specifically products used by cardiac surgeons to ablate cardiac tissue as a potential means to treat atrial fibrillation. The Company's core technology is the AtriLaze[TM] Cardiac Ablation System for use in cardiac tissue ablation procedures in open-heart surgery. The Company's common stock is traded on the OTC Bulletin Board under the symbol "MCVI.OB."
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 8, 2006
Words:174
Previous Article:Eldorado Exploration New Mexico Well Progress.
Next Article:Network Appliance Completes Acquisition of Topio.


Related Articles
MedicalCV to Present at Virtual OR Online Teaching Session To be held on Saturday, November 5, 2005.
MedicalCV Announces New Vice President of Sales; Company Moves to Next Phase of Business Development.
Pioneer of Cardiac Electrophysiology Joins MedicalCV Scientific Advisory Board.
Recent MedicalCV Transactions Significantly Strengthen Balance Sheet; Cash Position as of 12/31/2005 Approximates $12 Million; Warrant Liability...
MedicalCV Receives Third FDA 510(k) Clearance for Laser Technology; Company Advances Its Leadership Position in Laser Technology for a Stand-Alone,...
MedicalCV, Inc. Announces One-for-Ten Reverse Stock Split and Files Application to List Stock on Nasdaq Capital Market.
MedicalCV, Inc. Submits 510(k) Application to FDA for ATRILAZE(TM) Minimally Invasive System; Closed-Chest, Beating Heart System Designed to Ablate...
MedicalCV, Inc. Receives 4 Notices of Allowance on Laser-Based Cardiac Ablation Technology.
MedicalCV, Inc. Announces Completion of 1st AtriLaze(TM) Closed-Chest, Robotic Cardiac Ablation Procedure.
MedicalCV, Inc. Announces Completion of 1st Robotic Lone Cardiac Ablation Procedure.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters